A presidential announcement regarding lower costs for weight loss medications took a startling turn in the Oval Office when a man collapsed behind President Trump. The scene unfolded as executives from pharmaceutical companies were present, poised to discuss a significant deal.
The Commander-in-Chief visibly reacted to the sudden event, pausing his remarks and turning towards the source of the commotion. Staff immediately moved to assist, quickly ushering the press out of the room as medical attention was administered.
The individual was later identified as Gordon Findlay, an executive from Novo Nordisk. Press Secretary Karoline Leavitt confirmed he was receiving care and, thankfully, was reported to be alright following the incident.
The announcement, centered on agreements with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 drugs, was temporarily halted. CEO David Ricks, mid-sentence at the time, inquired about Findlay’s well-being, expressing concern for his condition.
Trump addressed reporters after the disruption, stating simply, “He’s fine. They just sent him out. He’s got doctors’ care.” Ricks later explained the Oval Office environment – prolonged standing and warmth – may have contributed to Findlay feeling faint.
The White House medical staff were praised for their swift and effective response, ensuring Findlay was quickly attended to and is now recovering well. Ricks reassured everyone that there was no cause for alarm.
This incident echoes a similar event in 2019, when a police recruit fainted during a speech by then-Prime Minister Boris Johnson. That event, also attributed to prolonged standing, briefly interrupted the proceedings.
Both instances highlight the physical strain that can accompany extended public appearances and the importance of readily available medical support during such events. The focus has now returned to the intended purpose of the Oval Office gathering: making vital medications more accessible.
